centre for drug design and discovery · 2010-01-08 · centre for drug design and discovery is the...

1
CENTRE FOR DRUG DESIGN AND DISCOVERY is the investment fund and technology transfer platform for early phase innovative drug discovery and target validation! MISSION CD3 STRATEGY Target Identifi- cation Target Validation Assay Develop- ment Screening Hit identi- fication Hit-to- Lead Lead Optimiza- tion Pre- clinical studies Clinical studies CD3 CLOSES THE GAP BETWEEN “ACADEMIC” BIOMEDICAL RESEARCH AND INDUSTRY UNIVERSITIES – RESEARCH INSTITUTES – SMALL BIOTECHS CD3 new targets new approaches and insights biology expertise biological assays (transfer) support in hit-to-lead process mechanism-of-action studies in vivo POC assay optimisation and HTS high quality compound libraries in silico drug design & screening pharma medicinal chemistry preliminary ADME-Tox in vivo POC project coordination and follow-up IP support … everything missing to reach goals PHARMA – BIOTECH INDUSTRY final lead optimisation pre-clinical development clinical development project planning production commercialisation marketing 1. “Screening projects” start = specific target or innovation 2. “Rational design projects” start = target with structural information 3. “Development or Hit-to-Lead projects” start = hit compounds Exceptionally 4. “Target identification or validation projects” start = non-drug like compound or non-validated target FOUR TYPES OF PROJECTS WITH DIFFERENT STARTING POINTS SELECTION PROCESS WITH INVESTMENT COMMITTEE & SCIENTIFIC ADVISORY BOARD www.lrd.kuleuven.be/CD3 Number of projects CD3 team SAB IC PARTNERS CONTACT Centre for Drug Design and Discovery, CD3 Minderbroedersstraat 12, B-3000 Leuven, BE Tel +32-16-32 65 23 [email protected] “Stimulating and optimizing the transformation of innovative European academic research results into small molecule drugs” “Supplement innovative biomedical research with everything lacking for professional small molecule drug discovery in order to develop drug lead compounds with in vivo POC” D D D D CD CD D D D D CD CD Centre Centre for for Drug Drug Design and Design and Discovery Discovery D D D D CD CD D D D D CD CD Centre Centre for for Drug Drug Design and Design and Discovery Discovery

Upload: others

Post on 08-Jul-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

CENTRE FOR DRUG DESIGN AND DISCOVERY

is the investment fund

and technology transfer

platform for early phase

innovative drug discovery

and target validation!

MISSION CD3 STRATEGY

TargetIdentifi-cation

TargetValidation

AssayDevelop-ment

ScreeningHit identi-fication

Hit-to-Lead

LeadOptimiza-tion

Pre-clinicalstudies

Clinicalstudies

CD3 CLOSES THE GAP BETWEEN “ACADEMIC” BIOMEDICAL RESEARCH AND INDUSTRY

UNIVERSITIES – RESEARCH INSTITUTES – SMALL BIOTECHS

CD3

• new targets• new approaches and insights• biology expertise• biological assays (transfer)• support in hit-to-lead process• mechanism-of-action studies• in vivo POC

• assay optimisation and HTS• high quality compound libraries• in silico drug design & screening• pharma medicinal chemistry• preliminary ADME-Tox• in vivo POC• project coordination and follow-up• IP support • … everything missing to reach goals

PHARMA – BIOTECHINDUSTRY

• final lead optimisation• pre-clinical development• clinical development• project planning• production• commercialisation• marketing

1. “Screening projects”start = specific target or innovation

2. “Rational design projects”start = target with structural information

3. “Development or Hit-to-Lead projects”start = hit compounds

Exceptionally4. “Target identification or validation projects”start = non-drug like compound or non-validated target

FOUR TYPES OF PROJECTS WITH

DIFFERENT STARTING POINTS

SELECTION PROCESS

WITH INVESTMENT

COMMITTEE &

SCIENTIFIC ADVISORY

BOARD

www.lrd.kuleuven.be/CD3

Number

of

projectsCD3 team

SAB

IC

PARTNERS

CONTACT Centre for Drug Design and Discovery, CD3Minderbroedersstraat 12, B-3000 Leuven, BE

Tel +32-16-32 65 [email protected]

“Stimulating and optimizing the transformation of

innovative European academic

research results into small

molecule drugs”

“Supplement innovative

biomedical research witheverything lacking for

professional small molecule

drug discovery in order to

develop drug lead compoundswith in vivo POC”

DDDDCDCDDDDDCDCDCentre Centre forfor DrugDrug

Design andDesign and

DiscoveryDiscovery DDDDCDCDDDDDCDCDCentre Centre forfor DrugDrug

Design andDesign and

DiscoveryDiscovery